» Articles » PMID: 39658701

Spermine Synthase Engages in Macrophages M2 Polarization to Sabotage Antitumor Immunity in Hepatocellular Carcinoma

Overview
Specialty Cell Biology
Date 2024 Dec 10
PMID 39658701
Authors
Affiliations
Soon will be listed here.
Abstract

Disturbances in tumor cell metabolism reshape the tumor microenvironment (TME) and impair antitumor immunity, but the implicit mechanisms remain elusive. Here, we found that spermine synthase (SMS) was significantly upregulated in tumor cells, which correlated positively with the immunosuppressive microenvironment and predicted poor survival in hepatocellular carcinoma (HCC) patients. Via "subcutaneous" and "orthotopic" HCC syngeneic mouse models and a series of in vitro coculture experiments, we identified elevated SMS levels in HCC cells played a role in immune escape mainly through its metabolic product spermine, which induced M2 polarization of tumor-associated macrophages (TAMs) and subsequently corresponded with a decreased antitumor functionality of CD8 T cells. Mechanistically, we discovered that spermine reprogrammed TAMs mainly by activating the PI3K-Akt-mTOR-S6K signaling pathway. Spermine inhibition in combination with immune checkpoint blockade effectively diminished tumor burden in vivo. Our results expand the understanding of the critical role of metabolites in regulating cancer progression and antitumor immunity and open new avenues for developing novel therapeutic strategies against HCC.

Citing Articles

Spermine accumulation via spermine synthase promotes tumor cell proliferation in head and neck squamous cell carcinoma.

Chen X, Song F, Xiao P, Yao Y, Li D, Fang Y BMC Cancer. 2025; 25(1):402.

PMID: 40045286 PMC: 11884143. DOI: 10.1186/s12885-025-13820-x.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A . Hepatocellular carcinoma. Lancet. 2022; 400(10360):1345-1362. DOI: 10.1016/S0140-6736(22)01200-4. View

3.
Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

4.
Fang Y, Zhan Y, Xie Y, Du S, Chen Y, Zeng Z . Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology. 2021; 75(6):1386-1401. PMC: 9299851. DOI: 10.1002/hep.32177. View

5.
Yang C, Zhang H, Zhang L, Zhu A, Bernards R, Qin W . Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022; 20(4):203-222. DOI: 10.1038/s41575-022-00704-9. View